Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Ustekinumab, Treatment for Plaque Psoriasis by Centocor and Janssen-Cilag

Drug (Brand/Generic)

Ustekinumab (CNTO 1275)

Company/Licensee

Centocor and Janssen-Cilag

Therapy Class

MAb

Product Description

Human anti-IL-12 and anti-IL-23 MAb

Current Indication

Moderate-to-severe plaque psoriasis

Market Sector

Dermatology

Development Status

Approved US and EU
Expand
Close
Close
Close

Go Top